Thera-SAbDab: the Therapeutic Structural Antibody Database

Overview

Journal Nucleic Acids Res

Publisher Oxford University Press

Specialty Biochemistry

Date 2019 Sep 27

PMID 31555805

Citations 68

Authors

Matthew I J Raybould

Claire Marks

Alan P Lewis

Jiye Shi

Alexander Bujotzek

Bruck Taddese

Charlotte M Deane

Affiliations

Soon will be listed here.

Abstract

The Therapeutic Structural Antibody Database (Thera-SAbDab; http://opig.stats.ox.ac.uk/webapps/therasabdab) tracks all antibody- and nanobody-related therapeutics recognized by the World Health Organisation (WHO), and identifies any corresponding structures in the Structural Antibody Database (SAbDab) with near-exact or exact variable domain sequence matches. Thera-SAbDab is synchronized with SAbDab to update weekly, reflecting new Protein Data Bank entries and the availability of new sequence data published by the WHO. Each therapeutic summary page lists structural coverage (with links to the appropriate SAbDab entries), alignments showing where any near-matches deviate in sequence, and accompanying metadata, such as intended target and investigated conditions. Thera-SAbDab can be queried by therapeutic name, by a combination of metadata, or by variable domain sequence - returning all therapeutics that are within a specified sequence identity over a specified region of the query. The sequences of all therapeutics listed in Thera-SAbDab (461 unique molecules, as of 5 August 2019) are downloadable as a single file with accompanying metadata.

Citing Articles

An antibody developability triaging pipeline exploiting protein language models.

Sweet-Jones J, Martin A MAbs. 2025; 17(1):2472009.

PMID: 40038849 PMC: 11901365. DOI: 10.1080/19420862.2025.2472009.

Unlocking the potential of approach in designing antibodies against SARS-CoV-2.

Subramaniam T, Mualif S, Chan W, Abd Halim K Front Bioinform. 2025; 5:1533983.

PMID: 40017562 PMC: 11865036. DOI: 10.3389/fbinf.2025.1533983.

YAbS: The Antibody Society's antibody therapeutics database.

Rawat P, Crescioli S, Prabakaran R, Sharma D, Greiff V, Reichert J MAbs. 2025; 17(1):2468845.

PMID: 40013403 PMC: 11869773. DOI: 10.1080/19420862.2025.2468845.

Learning the language of antibody hypervariability.

Singh R, Im C, Qiu Y, Mackness B, Gupta A, Joren T Proc Natl Acad Sci U S A. 2025; 122(1):e2418918121.

PMID: 39793083 PMC: 11725859. DOI: 10.1073/pnas.2418918121.

Predicting purification process fit of monoclonal antibodies using machine learning.

Maier A, Cha M, Burgess S, Wang A, Cuellar C, Kim S MAbs. 2025; 17(1):2439988.

PMID: 39782766 PMC: 11730362. DOI: 10.1080/19420862.2024.2439988.

References

Leem J, Dunbar J, Georges G, Shi J, Deane C . ABodyBuilder: Automated antibody structure prediction with data-driven accuracy estimation. MAbs. 2016; 8(7):1259-1268. PMC: 5058620. DOI: 10.1080/19420862.2016.1205773. View

Muhammed M, Aki-Yalcin E . Homology modeling in drug discovery: Overview, current applications, and future perspectives. Chem Biol Drug Des. 2018; 93(1):12-20. DOI: 10.1111/cbdd.13388. View

van Montfort R, Workman P . Structure-based drug design: aiming for a perfect fit. Essays Biochem. 2017; 61(5):431-437. PMC: 5869280. DOI: 10.1042/EBC20170052. View

Berman H, Westbrook J, Feng Z, Gilliland G, Bhat T, Weissig H . The Protein Data Bank. Nucleic Acids Res. 1999; 28(1):235-42. PMC: 102472. DOI: 10.1093/nar/28.1.235. View

Kaplon H, Reichert J . Antibodies to watch in 2019. MAbs. 2018; 11(2):219-238. PMC: 6380461. DOI: 10.1080/19420862.2018.1556465. View

Lima W, Gasteiger E, Marcatili P, Duek P, Bairoch A, Cosson P . The ABCD database: a repository for chemically defined antibodies. Nucleic Acids Res. 2019; 48(D1):D261-D264. PMC: 6943046. DOI: 10.1093/nar/gkz714. View

Steeland S, Vandenbroucke R, Libert C . Nanobodies as therapeutics: big opportunities for small antibodies. Drug Discov Today. 2016; 21(7):1076-113. DOI: 10.1016/j.drudis.2016.04.003. View

Steiner M, Neri D . Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends. Clin Cancer Res. 2011; 17(20):6406-16. DOI: 10.1158/1078-0432.CCR-11-0483. View

Raybould M, Marks C, Krawczyk K, Taddese B, Nowak J, Lewis A . Five computational developability guidelines for therapeutic antibody profiling. Proc Natl Acad Sci U S A. 2019; 116(10):4025-4030. PMC: 6410772. DOI: 10.1073/pnas.1810576116. View

10.

Dunbar J, Deane C . ANARCI: antigen receptor numbering and receptor classification. Bioinformatics. 2015; 32(2):298-300. PMC: 4708101. DOI: 10.1093/bioinformatics/btv552. View

11.

Jevsevar S, Kusterle M, Kenig M . PEGylation of antibody fragments for half-life extension. Methods Mol Biol. 2012; 901:233-46. DOI: 10.1007/978-1-61779-931-0_15. View

12.

Dunbar J, Krawczyk K, Leem J, Baker T, Fuchs A, Georges G . SAbDab: the structural antibody database. Nucleic Acids Res. 2013; 42(Database issue):D1140-6. PMC: 3965125. DOI: 10.1093/nar/gkt1043. View

13.

Labrijn A, Janmaat M, Reichert J, Parren P . Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019; 18(8):585-608. DOI: 10.1038/s41573-019-0028-1. View

14.

Grilo A, Mantalaris A . The Increasingly Human and Profitable Monoclonal Antibody Market. Trends Biotechnol. 2018; 37(1):9-16. DOI: 10.1016/j.tibtech.2018.05.014. View

15.

Benschop R, Chow C, Tian Y, Nelson J, Barmettler B, Atwell S . Development of tibulizumab, a tetravalent bispecific antibody targeting BAFF and IL-17A for the treatment of autoimmune disease. MAbs. 2019; 11(6):1175-1190. PMC: 6748573. DOI: 10.1080/19420862.2019.1624463. View

16.

Dunbar J, Krawczyk K, Leem J, Marks C, Nowak J, Regep C . SAbPred: a structure-based antibody prediction server. Nucleic Acids Res. 2016; 44(W1):W474-8. PMC: 4987913. DOI: 10.1093/nar/gkw361. View

17.

Al-Lazikani B, Lesk A, Chothia C . Standard conformations for the canonical structures of immunoglobulins. J Mol Biol. 1998; 273(4):927-48. DOI: 10.1006/jmbi.1997.1354. View

18.

Beck A, Goetsch L, Dumontet C, Corvaia N . Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017; 16(5):315-337. DOI: 10.1038/nrd.2016.268. View